|
Name |
Arugosin C
|
Molecular Formula | C25H28O6 | |
IUPAC Name* |
7,11-dihydroxy-17-(2-hydroxypropan-2-yl)-13-methyl-6-(3-methylbut-2-enyl)-2,15-dioxatetracyclo[8.7.1.03,8.014,18]octadeca-3(8),4,6,10,12,14(18)-hexaen-9-one
|
|
SMILES |
CC1=CC(=C2C3=C1OCC(C3OC4=C(C2=O)C(=C(C=C4)CC=C(C)C)O)C(C)(C)O)O
|
|
InChI |
InChI=1S/C25H28O6/c1-12(2)6-7-14-8-9-17-19(21(14)27)22(28)18-16(26)10-13(3)23-20(18)24(31-17)15(11-30-23)25(4,5)29/h6,8-10,15,24,26-27,29H,7,11H2,1-5H3
|
|
InChIKey |
MYJGUMZTENHAAQ-UHFFFAOYSA-N
|
|
Synonyms |
Arugosin C; 50875-10-0; CHEBI:68860; FD39J64RWK; UNII-FD39J64RWK; 6,8-dihydroxy-1-(2-hydroxypropan-2-yl)-4-methyl-9-(3-methylbut-2-en-1-yl)-1,12a-dihydrochromeno[4,5-bc][1]benzoxepin-7(2h)-one; MLS004257379; CHEMBL3092848; SMR003082511; Q15410264; 1,12a-Dihydro-6,8-dihydroxy-1-(1-hydroxy-1-methylethyl)-4-methyl-9-(3-methylbut-2-enyl)(1)benzopy rano(4,5-bc)(1)benzoxepin-7(2H)-one; 1,12a-Dihydro-6,8-dihydroxy-1-(1-hydroxy-1-methylethyl)-4-methyl-9-(3-methylbut-2-enyl)(1)benzopyrano(4,5-bc)(1)benzoxepin-7(2H)-one
|
|
CAS | 50875-10-0 | |
PubChem CID | 191158 | |
ChEMBL ID | CHEMBL3092848 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 424.5 | ALogp: | 5.0 |
HBD: | 3 | HBA: | 6 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 96.2 | Aromatic Rings: | 4 |
Heavy Atoms: | 31 | QED Weighted: | 0.607 |
Caco-2 Permeability: | -4.983 | MDCK Permeability: | 0.00001390 |
Pgp-inhibitor: | 0.145 | Pgp-substrate: | 0.005 |
Human Intestinal Absorption (HIA): | 0.07 | 20% Bioavailability (F20%): | 0.132 |
30% Bioavailability (F30%): | 0.007 |
Blood-Brain-Barrier Penetration (BBB): | 0.014 | Plasma Protein Binding (PPB): | 99.31% |
Volume Distribution (VD): | 0.527 | Fu: | 1.98% |
CYP1A2-inhibitor: | 0.336 | CYP1A2-substrate: | 0.484 |
CYP2C19-inhibitor: | 0.613 | CYP2C19-substrate: | 0.133 |
CYP2C9-inhibitor: | 0.751 | CYP2C9-substrate: | 0.849 |
CYP2D6-inhibitor: | 0.641 | CYP2D6-substrate: | 0.256 |
CYP3A4-inhibitor: | 0.314 | CYP3A4-substrate: | 0.296 |
Clearance (CL): | 3.786 | Half-life (T1/2): | 0.045 |
hERG Blockers: | 0.026 | Human Hepatotoxicity (H-HT): | 0.254 |
Drug-inuced Liver Injury (DILI): | 0.894 | AMES Toxicity: | 0.343 |
Rat Oral Acute Toxicity: | 0.567 | Maximum Recommended Daily Dose: | 0.473 |
Skin Sensitization: | 0.449 | Carcinogencity: | 0.596 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.608 |
Respiratory Toxicity: | 0.36 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004126 | 0.565 | D0Q0PR | 0.301 | ||||
ENC003568 | 0.509 | D07MGA | 0.261 | ||||
ENC003569 | 0.509 | D0AZ8C | 0.255 | ||||
ENC003968 | 0.509 | D04TDQ | 0.252 | ||||
ENC006093 | 0.482 | D0F7CS | 0.248 | ||||
ENC002916 | 0.482 | D01XWG | 0.247 | ||||
ENC002341 | 0.469 | D01XDL | 0.238 | ||||
ENC003963 | 0.462 | D07VLY | 0.234 | ||||
ENC003962 | 0.462 | D0C9XJ | 0.234 | ||||
ENC003942 | 0.453 | D0W6DG | 0.224 |